公开(公告)号：US20240327399A1

公开(公告)日：2024-10-03

申请号：US18660829

申请日：2024-05-10

Applicant: GlaxoSmithKline Intellectual Property (No.4) Limited ,  IDEAYA Biosciences, Inc.

Inventor： Janos BOTYANSZKI ,  Kevin Duffy ,  Young Eun Choi ,  Claire L. Neilan ,  Marcus M. Fischer

IPC: C07D417/14 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/675 ,  A61P35/00 ,  C07F9/6558

CPC classification number: C07D417/14 ,  A61K31/444 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/675 ,  A61P35/00 ,  C07F9/65583

Abstract: Disclosed herein are compounds of Formula (I):




that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helicase domain activity of Polθ. Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating and/or preventing diseases treatable by inhibition of Polθ such as cancer, including homologous recombination (HR) deficient cancers.

公开(公告)号：US20250090533A1

公开(公告)日：2025-03-20

申请号：US18708487

申请日：2022-11-11

Applicant: IDEAYA BIOSCIENCES, INC.

Inventor： Claire L. Neilan ,  Marcus M. Fischer ,  Kimberline Yang Gerrick ,  Neil E. Bhola

IPC: A61K31/519 ,  A61K31/337 ,  A61P35/00

Abstract: Provided herein is a combination of a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a taxane, and methods of using such combinations to treat diseases or disorders associated with MAT2A, for example, cancer.